Caroline Lemarchand - Onxeo SA Director
| C4X Stock | EUR 0.11 0.01 15.79% |
Director
Dr. Caroline Lemarchand serves as Preclinical RD Director, Member of the Executive Committee of Bioalliance Pharma SA since 2006. From 2002 to 2006, she served as Project Director in charge of developing new formulations for Bioalliance Pharma most advanced products. Previously, she worked at Hoechst Marion Roussel and Novartis Pharma. She is a Pharmacist and holds and a Doctor in Pharmaceutical Sciences. since 2006.
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Onxeo SA Management Efficiency
The company has return on total asset (ROA) of (0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Juan Mora | Meli Hotels International | 75 | |
| Luis Terminel | Meli Hotels International | 71 | |
| Fernando Silva | Meli Hotels International | 61 | |
| Maria Jaume | Meli Hotels International | 56 | |
| Francisco Garcia | Meli Hotels International | 64 | |
| Sebastian Jaume | Meli Hotels International | 53 | |
| Carina Lazaro | Meli Hotels International | 50 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 |
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | ||
| Russell Greig, Independent Member of the Board | ||
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | ||
| Daniele GuyotCaparros, Independent Member of the Board | ||
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | ||
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | ||
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | ||
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | ||
| Huiping Jiang, VP Assurance | ||
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | ||
| Thomas Hofstaetter, Independent Member of the Board | ||
| MD MPH, CEO Pres | ||
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | ||
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | ||
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | ||
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | ||
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | ||
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | ||
| David Solomon, Independent Member of the Board | ||
| Joseph Zakrzewski, Non-Executive Chairman of the Board | ||
| Louis Kayitalire, Vice President Head of Research & Development | ||
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | ||
| Nicolas Fellmann, CFO Director |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Onxeo SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |